Last reviewed · How we verify
RPX2014
At a glance
| Generic name | RPX2014 |
|---|---|
| Sponsor | Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company) |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- The Safety and Pharmacokinetics of Carbavance™ (RPX2014/RPX7009) in Subjects With Renal Insufficiency (PHASE1)
- Evaluating the Plasma, Epithelial Lining, and Alveolar Macrophage Concentrations of Intravenous Carbavance™ (RPX2014/RPX7009) in Healthy Adult Subjects (PHASE1)
- Safety, Tolerability, Pharmacokinetics of Intravenous RPX2014 and RPX7009 in Healthy Adult Subjects (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RPX2014 CI brief — competitive landscape report
- RPX2014 updates RSS · CI watch RSS
- Rempex Pharmaceuticals (a wholly owned subsidiary of The Medicines Company) portfolio CI